Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lesson Learned

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Feb 17, 2021 10:52pm

176 Views

Post# 32592702

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lesson Learned

If you consider analysis of facts to be pessimism & 'glass half empty' - so be it. The facts speak for themselves. I've been critical of management based on the factual aspects of their performance. If my perspective bothers you, feel free to ignore my posts.

I pointed out the fact that they still don't have enough cash to fully fund Phase 3 and operations during that duration. That doesn't mean that I want increased / further dilution; non-dilutive funding is obviously preferable. It's also a fact that warrants are a sign of weakness in a raise; again, I'm just pointing out facts.

I understand that you're happy that they sold about 20% of the company at a $210M valuation, with long-term, no acceleration warrants attached. I don't share that same view.

Arbourmark wrote:
Actually Ralph I have made numerous posts this evening supporting my reasons, so need to engage you. I have battled you in the past and placed you on ignore which I will again.

I am not here to pick fights. You have a glass half empty view, you have been critical of management on many occasions in the past, people can simply view your history.

Time will tell, the sp may drop due to bought deal or trade sideways for consolidation. The facts are the share price has had a good run, yesterday was around $6 and today $7. Management made a great call as share price was due to pull back after rapid rise. It will take a brief breather and consolidate and return to climbing to $15 area. You comment that the $20M from Nuance + $35M from today's bought deal is not enough but complain about previous raise in the summer which also has warrants attached which I own plus today has warrants and these provide additional funds. You make no sense and view ATE with a very negative view, I am sure you would criticize management tomorrow if they announced a $5B buyout.